Encompass Health Corporation
NYSE:EHCMedical - Care Facilities
-$1.95 today
- Market cap
- $13.24B
- Beta
- 0.59
- P/E (TTM)
- 15.9
- EPS (TTM)
- $6.14
- Dividend yield
- 0.76%
Volume 0.84M
Average 0.92M
EHC Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Encompass Health CorporationNYSE: EHC
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures growth accelerates
Q2 FY2026 capital expenditures of $220.3M (cash outflow) rose 40.4% year over year, ahead of the +19.9% change in trailing-twelve-month capital expenditures. Sequentially, it rose 35.7% from the prior quarter. Over 3 fiscal years it compounded at +8.0% a year.
Context
- Capital expenditures amounted to 12.4% of revenue in FY2025, up 0.4 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +40.4% holds above the trailing-twelve-month pace of +19.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (736.4M) USD
- Year-over-year change
- -14.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (736.4M) | -14.6% |
| FY2024 | 2024-12-31 | (642.5M) | -10.2% |
| FY2023 | 2023-12-31 | (583.1M) | +0.2% |
| FY2022 | 2022-12-31 | (584.1M) | -6.0% |
| FY2021 | 2021-12-31 | (551.2M) | — |
Capital Expenditures vs competitors
How EHC compares with its peers on the latest reported figures
- EHC's LTM Jun 2026 capital expenditures of $799.1M is the largest of the 9 companies compared; the peer median is $35.6M.
- Its year-over-year change of +19.9% is the 6th highest of 9, against a peer median of +36.4%.
- Capital expenditures amounts to 12.9% of revenue for EHC, versus a peer median of 2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $799.1M | +19.9% | +8.0% | 12.9% | |
| LTM Jun 2026 | $189.34M | +1.7% | +30.3% | 3.5% | |
| LTM Jun 2026 | $117.47M | -36.6% | +66.4% | 2.1% | |
| LTM Jun 2026 | $66.35M | +19.8% | +3.1% | 2.6% | |
| LTM Sep 2026 | $46.05M | +34.6% | +6.5% | 2.9% | |
| LTM Sep 2026 | $25.15M | +143.2% | +5.3% | 0.4% | |
| LTM Mar 2026 | $18.77M | +113.1% | +15.8% | 1.8% | |
| LTM Oct 2026 | $9.7M | +38.1% | -14.7% | 0.4% | |
| LTM Jun 2026 | $9.34M | +38.1% | -2.4% | 0.6% | |
| Peer median (excluding EHC) | $35.6M | +36.4% | +5.9% | 2.0% | |
Competitors are the stored peer set for EHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 517.6M | 365.9M | 361.6M | 599.4M | 567.2M |
| Depreciation & Amortization | 219.6M | 243.6M | 273.9M | 299.6M | 327.9M |
| Deferred Income Tax | 17.4M | 27.9M | 3.9M | 10.7M | 22.3M |
| Stock-Based Compensation | 29.1M | 29.2M | 50.6M | 48.3M | 0 |
| Change in Working Capital | (118M) | (30.4M) | 50.3M | 21.9M | 4.3M |
| Accounts Receivables | (64.3M) | (16.9M) | (22.4M) | 3M | (15.2M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 14.9M | 2.3M | 11.8M | 3M | (22.6M) |
| Other Working Capital | (68.6M) | (15.8M) | 60.9M | 15.9M | 42.1M |
| Other Non-Cash Items | 50.1M | 69.6M | 110.5M | 22.9M | 253.9M |
| Operating Cash Flow | 715.8M | 705.8M | 850.8M | 1B | 1.18B |
| Capital Expenditures | (551.2M) | (584.1M) | (583.1M) | (642.5M) | (736.4M) |
| Acquisitions (Net) | (118.6M) | 64.1M | 0 | 0 | 0 |
| Purchases of Investments | (9M) | (35.2M) | (23M) | (22.5M) | (184.4M) |
| Sales of Investments | 9M | (64.1M) | 0 | 18.9M | 172.8M |
| Other Investing Activities | 3.5M | (7.7M) | 3.3M | (7.2M) | (14.8M) |
| Investing Cash Flow | (666.3M) | (627M) | (602.8M) | (653.3M) | (762.8M) |
| Debt Repayment | (59.1M) | (498.2M) | (83.3M) | (242M) | (29M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (14.6M) | (7.3M) | (8.2M) | (31.1M) | (158M) |
| Dividends Paid | (112.2M) | (99M) | (60.4M) | (62.8M) | (71.1M) |
| Other Financing Activities | (54.2M) | 458.8M | (45.3M) | 5.3M | (174.9M) |
| Financing Cash Flow | (240.1M) | (145.7M) | (197.2M) | (330.6M) | (433M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (190.6M) | (66.9M) | 50.8M | 18.9M | (20.2M) |
| Free Cash Flow | 164.6M | 121.7M | 267.7M | 360.3M | 439.2M |
Encompass Health Corporation
NYSE:EHC
Intrinsic Alpha fair value
Locked
Current Price
$134.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.